drugset / Trial / NCT05734495
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Phase 2
Active not recruiting
46 enrolled
Dana-Farber Cancer Institute
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Timeline
- Start
- 2023-05-02
- Primary completion
- 2029-01-25
- Completion
- 2033-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirtobrutinib | Other / unclassified | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |